Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma

[1]  M. Tsao,et al.  KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  S. Moon,et al.  Effective method for the isolation and proliferation of primary lung cancer cells from patient lung tissues , 2013, Biotechnology Letters.

[3]  M. Spitz,et al.  Role of Selected Genetic Variants in Lung Cancer Risk in African Americans , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  T. Stinchcombe,et al.  KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Parasuraman,et al.  EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.

[6]  Y. Yatabe,et al.  Surgery for NSCLC in the era of personalized medicine , 2013, Nature Reviews Clinical Oncology.

[7]  Mishal N. Patel,et al.  Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.

[8]  L. Ma,et al.  Meta-analysis demonstrates lack of association of the hOGG1 Ser326Cys polymorphism with bladder cancer risk. , 2012, Genetics and molecular research : GMR.

[9]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[10]  A. Powers,et al.  Comparative Effectiveness of Dalteparin and Enoxaparin in a Hospital Setting , 2012, Journal of pharmacy practice.

[11]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[12]  R. Motzer,et al.  NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  Y. Bang,et al.  Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes , 2011, Cellular Oncology.

[14]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[15]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[16]  H. Ji,et al.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Nakanishi,et al.  Lung Cancer Risk and Genetic Polymorphisms in DNA Repair Pathways: A Meta-Analysis , 2010, Journal of nucleic acids.

[18]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[19]  L. Benesova,et al.  Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. , 2010, Anticancer research.

[20]  T. Mitsudomi,et al.  Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation , 2010, Cancer and Metastasis Reviews.

[21]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[22]  Juan Yang,et al.  Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients , 2010, Acta Pharmacologica Sinica.

[23]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[24]  M Eileen Dolan,et al.  Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy , 2009, Clinical Cancer Research.

[25]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[26]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[27]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[28]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[29]  C. Eaves,et al.  Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity. , 2005, Methods in molecular biology.

[30]  M. Feldman,et al.  Genetic Structure of Human Populations , 2002, Science.

[31]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[32]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[33]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[34]  J. Minna,et al.  Comparison of features of human lung cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Minna,et al.  Comparison of features of human breast cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  P. Sutphin,et al.  The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent , 1998, Molecular and Cellular Biology.

[37]  L. Neckers,et al.  Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[39]  J. Momand,et al.  Heat Shock Protein 84 Forms a Complex with Mutant p53 Protein Predominantly within a Cytoplasmic Compartment of the Cell* , 1996, The Journal of Biological Chemistry.

[40]  A. Gazdar,et al.  Cell culture methods for the establishment of the NCI series of lung cancer cell lines , 1996, Journal of cellular biochemistry. Supplement.

[41]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[42]  R. Link,et al.  Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. , 1989, The Journal of investigative dermatology.

[43]  A. Levine,et al.  Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines , 1987, Molecular and cellular biology.

[44]  J. Minna,et al.  Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.